A federal judge in Camden, New Jersey, dismissed a suit accusing lawyers from Mazie, Slater, Katz & Freeman of collecting excessive contingency fees in the $358 million settlement of multidistrict litigation over alleged defects in the blood pressure drug Olmesartan.

The attorneys have framed the dispute as one among former law partners, now embroiled in a “longstanding vendetta” since their firm’s breakup.